PDI expecting cuts from AstraZeneca: Reuters

Share this article:
Sales and marketing services provider PDI expects significant reductions in the 800 sales reps it contracts with AstraZeneca, according to a Reuters report. The reductions came as part of discussions with AstraZeneca over the status of fees for service contract sales engagements. AstraZeneca said it would comment further once it has more information about the scope and timing of the changes, the report said.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.